Abstract
Hepatic Encephalopathy (HE) is a serious neuropsychiatric condition of both acute and chronic liver failure. Acute liver failure is characterized by rapid evolution of HE and by brain edema. Portal-Systemic encephalopathy (PSE) is particularly prevalent following treatment of portal hypertension or ascites by the TIPS procedure. Available evidence currently suggests that neurotransmission changes rather than brain energy failure are the primary cause of HE. Recent studies both in autopsied brain tissue from HE patients as well as in experimental animal models of HE reveal that liver failure results in altered expression of several genes coding for proteins having key roles in the control of neuronal excitability. Such alterations include decreased expression of the glutamate transporter GLT-1, and increased expression of monoamine oxidase (MAO-A isoform), the “peripheral-type” benzodiazepine receptor (PTBR) as well as constitutive neuronal nitric oxide synthase (nNOS). Such changes result in altered protein expression and in increased extracellular brain glutamate, increased degradation of monoamine neurotransmitters, increased synthesis of neurosteroids with inhibitory properties, and increased production of nitric oxide (respectively) in brain in chronic liver failure. In the case of GLT-1, PTBR, and nNOS, alterations in expression result from exposure to ammonia and/or manganese, two neurotoxic agents shown previously to be increased in brain in liver failure.
Similar content being viewed by others
REFERENCES
Anholt, R.R.H. (1986). Mitochondrial benzodiazepine receptors as potential modulators of intermediary metabolism. Trends. Pharmacol. Sci. 7:506–511.
Audet, R., and Butterworth, R.F. (1998). Portacaval anastomosis results in more widespread alterations of cerebral metabolism in old versus young adult rats: Implications for post-shunt encephalopathy. Metab. Brain Dis. 13:69–78.
Barbara, L., Barbiroli, B., Gaiani, S., Bolondi, L., Sofia, S., Lodi, R., Iotti, S., Zaniol, P., Sama, C., and Brillanti, S. (1992). Abnormal brain energy metabolism assessed by 31P-magnetic resonance spectroscopy in patients with liver disease (Abstract). Hepatology 16:165.
Bates, T.E., Williams, S.R., Kauppinen, R.A., and Godian, D.G. (1989). Monoamines and metabolites in an animal model of acute liver failure in vivo: 1H and 31P nuclear magnetic resonance study. J. Neurochem. 53:102–110.
Bergeron, M., Reader, T.A., Pomier Layrargues, G., and Butterworth, R.F. (1989). Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem. Res. 14:853–859.
Bergeron, M., Swain, M.S., Reader, T.A., and Butterworth, R.F. (1995). Increased mesocortical dopaminergic function following ammonia administration to rats with portacaval anastomosis. Neurochem. Res. 10:79–86.
Butterworth, R.F. (1991). Pathophysiology of hepatic encephalopathy: The ammonia hypothesis revisited. In (F. Bengtsson, ed.) Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange, CRC Press, Boca Raton, pp. 9–24.
Butterworth, R.F. (1998). Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy. Metab. Brain Dis. 13:339–347.
Butterworth, R.F., Giguère, J.F., Michaud, J., Lavoie, J., and Pomier Layrargues, G. (1987). Ammonia: Key factor in the pathogenesis of hepatic encephalopathy. Neurochem. Pathol. 6:1–12.
Butterworth, R.F., Spahr, L., Fontaine, S., and Pomier Layrargues, G. (1995). Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab. Brain Dis. 4:259–267.
Chamuleau, R.A.F.M., Bosman, D.K., Bovée, W.M.M.J., Luyten, P.R., and Barkhof, F. (1991). Chronic hepatic encephalopathy studied by NMR spectroscopy and MRI in man (Abstract). J. Hepatol. 13:S13.
Chan, H., Hazell, A.S., Desjardins, P., and Butterworth, R.F. (2000). Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem. Int. 37:243–248.
Clemmensen, J.O., Larsen, F.S., Kondrup, J., Hansen, B.A., and Ott, P. (1999). Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29:648–653.
Cruz, N.F., and Duffy, T.E. (1983). Local cerebral glucose metabolism in rats with chronic portacaval shunts. J. Cereb. Blood Flow Metab. 3:311–320.
Desjardins, P., Bandeira, P., Raghavendra Rao, V.L., Ledoux, S., and Butterworth, R.F. (1997). Increased expression of the peripheral-type benzodiazepine receptor-isoquinoline carboxamide binding protein in mRNA brain following portacaval anastomosis. Brain Res. 758:255–258.
Devenyi, A.G., Barron, T.F., and Mamourian, A.C. (1994). Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagille's syndrome. Gastroenterology 106:1068–1071.
DeWaele, J.P., Audet, R.M., Leong, D.K., and Butterworth, R.F. (1996). Portacaval anastomosis results in region selective-changes of β-endorphin content and of μ and δ opioid receptor densities in rat brain. Hepatology 24:895–901.
DeWaele, J.P., Audet, R.M., Rose, C., and Butterworth, R.F. (1997). The portacaval-shunted rat: A new model for the study of the mechanisms controlling voluntary ethanol consumption and ethanol dependence. Alcohol. Clin. Exp. Res. 21:305–310.
Fan, P., Lavoie, J., Le, N.L.O., Szerb, J.C., and Butterworth, R.F. (1990). Neurochemical and electrophysiological studies on the inhibitory effect of ammonium ions on synaptic transmission in slices of rat hippocampus: Evidence for a postsynaptic action. Neuroscience 37:327–324.
Giguère, J.F., Hamel, E., and Butterworth, R.F. (1992). Increased densities of binding sites for the “peripheraltype” benzodiazepine receptor ligand 3H-PK11195 in rat brain following portacaval anastomosis. Brain Res. 585:295–298.
Hauser, R.A., Zesiewicz, T.A., Rosemurgy, A.S., Martinez, C., and Olanow, C.W. (1994). Manganese intoxication and chronic liver failure. Ann. Neurol. 36:871–875.
Hazell, A.S., Desjardins, P., and Butterworth, R.F. (1999). Exposure of primary astrocyte cultures to manganese results in increased binding sites for the “peripheral-type” benzodiazepine receptor ligand 3H-PK11195. Neurosci. Lett. 271:5–8.
Hindfelt, B., Plum, F., and Duffy, T.E. (1977). Effects of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J. Clin. Invest. 59:386–396.
Itzhak, Y., and Norenberg, M.D. (1994). Ammonia-induced upregulation of peripheral-type benzodiazepine receptors in cultured astrocytes labeled with 3H-PK11195. Neurosci. Lett. 177:35–38.
Jalan, R., Turjanski, N., Taylor-Robinson, S.D., Koepp, M.J., Richardson, M.P., Wilson, J.A., Bell, J.D., and Brooks, D.J. (2000). Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut. 46:546–552.
Knecht, K., Michalak, A., Rose, C., Rothstein, J.D., and Butterworth, R.F. (1997). Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci. Lett. 229:201–203.
Kulisevsky, J., Pujol, J., Balauzo, J., Junqué, C., Deus, J., Capdevilla, A., and Villanueva, C. (1992). Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations. Hepatology 16:1382–1388.
Lai, J.C.K., and Cooper, A.J.L. (1986). Brain α-ketoglutarate dehydrogenase: Kinetic properties, regional distribution and effects of inhibitors. J. Neurochem. 47:76–1386.
Lavoie, J., Giguère, J.F., Pomier Layrargues, G., and Butterworth, R.F. (1987). Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab. Brain Dis. 2:283–290.
Lavoie, J., Pomier Layrargues, G., and Butterworth, R.F. (1990). Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 11:874–878.
Lockwood, A.H., Murphy, B.W., Donnelly, K.Z., Mahl, T.C., and Perini, S. (1993). Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 18:1061–1068.
Lockwood, A.H., Yap, E.W.H., Rhoades, H.M., and Wong, W. (1991a). Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J. Cereb. Blood Flow Metab. 11:331–336.
Lockwood, A.H., Yap, E.W.H., and Wong, W-H. (1991b). Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J. Cereb. Blood Flow Metab. 11:337–341.
Michalak, A., Rose, C., Butterworth, J., and Butterworth, R.F. (1996). Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology 24:908–913.
Mirowitz, S.A., Westrich, J.J., and Hirsch, J.D. (1991). Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology 181:177–120.
Mousseau, D.D., Baker, G.B., and Butterworth, R.F. (1997). Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J. Neurochem. 68:1200–1208.
Mousseau, D.D., Perney, P., Pomier Layrargues, G., and Butterworth, R.F. (1993). Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci. Lett. 162:192–196.
Norenberg, M.D. (1981). The astrocyte in liver disease. Adv. Cell. Neurobiol. 2:303–352.
Norenberg, M.D., Mozes, L.W., Papendick, R.E., and Norenberg, L.O.B. (1985). Effect of ammonia on glutamate, GABA and rubidium uptake by astrocytes. Ann. Neurol. 18:149.
Panerai, A.E., Salerno, F., Baldissera, F., Martini, A., Di Giulio, A.M., and Mantegazza, P. (1982). Brain β-endorphin concentrations in experimental chronic liver disease. Brain Res. 247:188–190.
Peterson, C., Giguère, J.F., Cotman, C.W., and Butterworth, R.F. (1990). Selective loss of NMDA-sensitive 3H-glutamate binding sites in rat brain following portacaval anastomosis. J. Neurochem. 55:386–390.
Pomier Layrargues, G., Spahr, L., and Butterworth, R.F. (1995). Increased manganese concentrations in pallidum of cirrhotic patients: Cause of magnetic resonance hyperintensity? Lancet 345:735.
Raabe, W.A. (1989). Neurophysiology of ammonia intoxication. In (R.F. Butterworth and G. Pomier Layrargues, eds.) Hepatic Encephalopathy: Pathophysiology and Treatment, Humana Press, Clifton, NJ, pp. 49–77.
Raghavendra Rao, V.L., Audet, R.M., and Butterworth, R.F. (1997a). Increased neuronal nitric oxide synthase expression in brain following portacaval anastomosis. Brain Res. 765:169–172.
Raghavendra Rao, V.L., Audet, R.M., and Butterworth, R.F. (1997b). Portacaval shunting and hyperammonemia stimulate the uptake ofL-3H-arginine but not of L-3H-nitroarginine into rat brain synaptosomes. J. Neurochem. 68:337–343.
Raghavendra Rao, V.L., Audet, R., Therrien, G., and Butterworth, R.F. (1994). Tissue specific alterations of binding sites for the peripheral-type benzodiazepine receptor ligand 3H-PK11195 in rats following portacaval anastomosis. Digest. Dis. Sci. 39:1055–1063.
Raghavendra Rao, V.L., and Butterworth, R.F. (1994). Alterations of [3H]8-OH-DPAT and [3H]-ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurosci. Lett. 182:69–72.
Raghavendra Rao, V.L., and Butterworth, R.F. (1998). Neuronal nitric oxide synthase and hepatic encephalopathy. Metab. Brain Dis. 12:175–189.
Raghavendra Rao, V.L., Giguère, J.F., Pomier Layrargues, G., and Butterworth, R.F. (1993a). Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res. 621:349–352.
Raghavendra Rao, V.L., Qureshi, I.A., and Butterworth, R.F. (1993b). Increased densities of binding sites for the peripheral-type benzodiazepine ligand 3H-PK11195 in congenital ornithine transcarbamylase deficient sparse-fur mouse. Pediat. Res. 34:777–780.
Rose, C., Butterworth, R.F., Zayed, J., Normandin, L., Todd, K., Michalak, A., Spahr, L., Huet, P.-M., Pomier Layrargues, G. (1999). Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 117: 640–644.
Ross, B.D., Morgan, M.Y., Cox, I.J., Hawley, K.E., and Young, I.R. (1987). Continuing defect in cerebral energy metabolism in patients with persistent encephalopathy (PHE): Monitoring with 31P MRS (Abstract). Clin. Sci. 72:26P.
Spahr, L., Butterworth, R.F., Fontaine, S., Bui, L., Therrien, G., Millette, P., Lebrun, L.-H., Zayed, J., Leblanc, A., and Pomier Layrargues, G. (1996). Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 24:1116–1120.
Spahr, L., Butterworth, R.F., Fontaine, S., Therrien, G., LeBlanc, A., Lavoie, J., and Pomier Layrargues, G. (1995). Increased manganese (Mn2+) in blood and in pallidum of cirrhotic patients with hepatic encephalopathy: Factor responsible for magnetic resonance (MR) signal hyperintensity? Gatroenterology 108:A1176.
Taylor-Robinson, S.D., Sargentoni, J., Mallalieu, R.J., Bell, J.D., Bryant, D.J., Coutts, G.A., and Morgan, M.Y. (1994). Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 20:1173–1178.
Versieck, J., Barbier, F., Speecke, A., and Hoste, J. (1974). Manganese, copper and zinc concentrations in serum and packed blood cells during acute hepatitis, chronic hepatitis and posthepatic cirrhosis. Clin. Chem. 20:1141–1145.
Young, S.N., and Lal, S. (1980). CNS tryptamine metabolism in hepatic coma. J. Neural Transm. 47:153–161.
Zeneroli, M.L., Baraldi, M., Ventura, E., Zanoli, P., Vezzeli, C., Russo, A.M. (1988). Beta-endorphin and opiate receptor changes in acute and chronic models of hepatic encephalopathy. In (R.F. Butterworth and G. Pomier Layrargues, eds.) Hepatic Encephalopathy: Pathophysiology and Treatment, Humana Press Clifton, NJ, pp. 455–466.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Butterworth, R.F. Neurotransmitter Dysfunction in Hepatic Encephalopathy: New Approaches and New Findings. Metab Brain Dis 16, 55–65 (2001). https://doi.org/10.1023/A:1011614528751
Issue Date:
DOI: https://doi.org/10.1023/A:1011614528751